Jiangxi-Led Provincial Alliance Bids for Renal Function and Myocardial Enzyme Biochemical Reagents, Accelerating IVD Sector's Volume-Based Procurement
Abbott
Diagnostic and pharmaceutical product manufacturers
Roche
Oncology Drug Research, Development, and Manufacturing
Beckman Coulter
Diagnostic Product Developer
Siemens Healthineers
Medical Solutions Provider
Mindray
Medical Device R&D Manufacturer
Zybio
Developer, Manufacturer, and Distributor of In Vitro Diagnostic (IVD) Reagents and Instruments
| Lead Rise Individual Thigh |
Name | Relevant | Change Range |
|---|---|---|---|
| Northland | Research Report Cash Flow | 7.51% | |
| Renbio | Research Report Cash Flow | 3.01% | |
| Cowin Century | Research Report Cash Flow | 3.01% | |
| Yongshun Biological | Research Report Cash Flow | 2.72% | |
| Click to view all>> | |||
| Resources Gold Flow Entry |
Name | Relevant | Net Inflow (10,000) |
|---|---|---|---|
| Wantai Bio | Research Report Capital Flow | 2611.69 | |
| ZhiXiang JinTai-U | Research Report Cash Flow | 1363.91 | |
| Tiantan Bio | Research Report Capital Flow | 1268.43 | |
| Tonghua Dongbao | Research Report Capital Flow | 1133.67 | |
| Click to view all>> | |||
Industry Information.
According to the official WeChat account of Jiangxi Provincial Medical Security Bureau, on December 21, the public information conference for the inter-provincial alliance centralized bulk procurement of renal function and myocardial enzyme biochemical test reagents led by Jiangxi in twenty-four provinces (regions, corps) was held in Nanchang, and the proposed winning results were generated. According to statistics, the average price reduction of the selected products in this centralized procurement is about 77%.
Commentary.
Jiangxi Leads the Kidney Function and Myocardial Enzyme Biochemical Reagent Centralized Procurement Bid Opening, Accelerating the Implementation of IVD Sector Centralized Procurement. According to statistics, this alliance procurement selected 28 types of products, including heart-type fatty acid-binding protein, lipoprotein-associated phospholipase A2, neutrophil gelatinase-associated lipocalin, homocysteine, myeloperoxidase, troponin I, and other high-priced varieties. Based on demand volume and the number of medical institutions reporting demand, A and B bidding groups were distinguished, and selection rules were set. Approximately 23,800 medical institutions participated in the procurement volume declaration, with an annual total procurement demand of 820 million ml (per person). In this centralized bulk procurement, the selection rate for Group A enterprises, which have larger procurement volumes, exceeded 99%, including imported companies such as Roche, Abbott, Beckman Coulter, Siemens Healthineers, and domestic companies like Mindray, Zybio, Inc., and Medicalsystem Biotechnology Co., Ltd. We believe that the gradual expansion of centralized procurement in the in vitro diagnostic reagent sector is a trend, and the substitution rate of domestically produced products is expected to increase further.
Risk Warning. Risks from intensified medical insurance cost control, valuation fluctuation risks, new product R&D failure risks, new product sales not meeting expectations, risks from new competitors entering the market, and market fluctuation risks, etc.